Chimerix

2011

Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences

 159.52 KB

DURHAM, NC, November 9, 2011 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences in New York City: the 8th…

> Read More

Chimerix Honored with "2011 Southeast Bio Deal of the Year: Venture Capital Transaction" Award

 214.33 KB

DURHAM, NC, November 7, 2011 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, was presented with the "2011 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO)…

> Read More

Chimerix Announces Late-Breaker Presentation at 51st ICAAC Annual Meeting

 29.24 KB

- CMX001 shows no nephrotoxicity or myelosuppression in 183 patients treated under emergency INDs

DURHAM, NC, September 16, 2011 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that investigators will…

> Read More

Chimerix Named by CED as a Top 25 2011 North Carolina Companies To Watch

August 8, 2011, Research Triangle Park - Chimerix has been selected by CED as one of 25 "NC Companies to Watch." CED, a private, nonprofit organization that promotes entrepreneurial efforts in North Carolina, has named 25 winners for the second annual North Carolina Companies To Watch…

> Read More

Chimerix Commences Phase 2 Study of CMX001 for Prevention of AdV in Ped & Adult Hematopoietic Stem Cell Transplant Patients

 92.92 KB

- CMX001 Granted FDA Fast-Track Designation for Adenovirus Indication --

DURHAM, NC, JULY 13, 2011 - Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized,…

> Read More

Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract

 113.73 KB

- BARDA Deletes 12 Million Optional Courses from SIGA Sole Source Contract Allowing Opportunity for Competitive Procurement of a Second Smallpox Antiviral

DURHAM, NC, June 27, 2011 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics,…

> Read More